$3.05
-0.09-2.87%
At close: Nov 13, 4:00 PM EST
$3.11
0.06112%
After Hours: 4:26 PM EST
Galectin Therapeutics Inc
GALTNASDAQ
Galectin Therapeutics fell 43.2% from $5.53 to $3.14, behind the S&P 500's +12.3%. Its worst day was Dec 19 (−28.9%), and its low came May 19 at $2.08.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.13 missed the $-0.11 estimate on $0.00 revenue.
−0.4% · S&P 500 0.0%
Galectin Therapeutics closed at its highest level of the year, 17.7% above where the year started.
Story events cover the past 12 months · Times ET
+4.2% · S&P 500 −0.2%
EPS of $-0.08 beat the $-0.10 estimate on $0.00 revenue.
+8.6% · S&P 500 +2.9%
EPS of $-0.08 missed the $-0.06 estimate on $0.00 revenue.
−7.7% · S&P 500 −1.2%
Galectin Therapeutics shares rose 25.6%, while the S&P 500 fell 0.0%.
+25.6%, the year's best day · S&P 500 0.0%
Galectin Therapeutics shares rose 16.1%, while the S&P 500 rose 0.4%.
+16.1% · S&P 500 +0.4%
EPS of $-0.14 missed the $-0.09 estimate on $0.00 revenue.
−2.5% · S&P 500 −0.2%
Where it ended: a close of $3.14 on Nov 12, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.05).
Nothing in the past 12 months.
All GALT dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GALT and SPY from Benzinga historical bars. Not investment advice.
